<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 03 Apr 2025 10:12:29 +0000</lastbuilddate>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175709/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>Clonal haematopoiesis is the clonal expansion of blood stem cells with acquired mutations. Clonal haematopoiesis of indeterminate potential (CHIP), traditionally defined as clonal haematopoiesis driven by a pre-leukaemic mutation in at least 2% of sequenced alleles, affects 10-20% of individuals aged >;70 years. Although CHIP is considered a precursor condition for haematological malignancies, population-based data suggest that the majority of CHIP-associated mortality is attributable to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Apr 2. doi: 10.1038/s41569-025-01148-9. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Clonal haematopoiesis is the clonal expansion of blood stem cells with acquired mutations. Clonal haematopoiesis of indeterminate potential (CHIP), traditionally defined as clonal haematopoiesis driven by a pre-leukaemic mutation in at least 2% of sequenced alleles, affects 10-20% of individuals aged >;70 years. Although CHIP is considered a precursor condition for haematological malignancies, population-based data suggest that the majority of CHIP-associated mortality is attributable to non-malignant conditions, such as cardiovascular disease. Observational human studies have shown that CHIP is a strong and independent predictor of the onset and progression of atherosclerotic cardiovascular disease, heart failure and arrhythmia. In addition, findings from animal experiments suggest that CHIP is causally involved in these diseases and might be a risk factor that can be targeted with therapeutics. As our understanding of the cardiovascular implications of CHIP and other types of clonal haematopoiesis rapidly expands, it has become increasingly clear that clonal haematopoiesis subtypes have substantial heterogeneity with respect to magnitude of effect and underlying mechanisms for different cardiovascular diseases. In this Review, we discuss clonal haematopoiesis as a prognostic factor for numerous cardiovascular diseases, highlight its potential as a therapeutic target and propose a potential role for CHIP in cardiovascular precision medicine.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175709/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40175709</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01148-9>10.1038/s41569-025-01148-9</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175709</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Art Schuermans</dc:creator>
<dc:creator>Michael C Honigberg</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target</dc:title>
<dc:identifier>pmid:40175709</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01148-9</dc:identifier>
</item>
<item>
<title>The Cardiovascular Care of the Pediatric Athlete</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175017/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>Sports cardiology broadly encompasses the cardiovascular care of individuals who place a high premium on habitual exercise, sports performance, and/or sports competition. Some of the essential aspects within sports cardiology include the preparticipation cardiac evaluation and the management of cardiac diseases in athletes. Although most sports cardiology practitioners are trained in adult cardiology, a significant number of individuals who participate in sports are pediatric-aged, &lt;18 years...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1434-1454. doi: 10.1016/j.jacc.2025.02.010.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Sports cardiology broadly encompasses the cardiovascular care of individuals who place a high premium on habitual exercise, sports performance, and/or sports competition. Some of the essential aspects within sports cardiology include the preparticipation cardiac evaluation and the management of cardiac diseases in athletes. Although most sports cardiology practitioners are trained in adult cardiology, a significant number of individuals who participate in sports are pediatric-aged, &lt;18 years old. Up to two-thirds of children in middle and high school participate in organized sports or are involved in nonorganized recreational sports. The cardiovascular care of pediatric-aged athletes can be challenging because many of the classic tenets and principles in adult sports cardiology do not fully generalize to pediatrics, and there is a lack of the evidence base that may be present for adult athletes. The epidemiology, presentation, and progression of cardiovascular diseases can be significantly different between pediatric and adult athletes. The evaluation of potential diseases and management considerations may also differ between pediatric and adult athletes. Similar to adults, there are "gray zones" where it is difficult to differentiate between normal exercise-induced cardiac remodeling and true cardiac pathology, but the additional lack of normative standards further complicates assessments in pediatric athletes. Management decisions for pediatric athletes are generally based on limited data but carry substantial short- and long-term implications. Thus, shared decision-making as part of the determination of clinical management strategies and for sports participation is critical and requires the participation of the parents or guardian(s). In this state-of-the-art review, key differences between pediatric and adult-aged athletes are highlighted. Specifically, how to define the "pediatric athlete," consider cardiovascular adaptations observed among pediatric athletes, determine preparticipation screening options and optimal symptom-driven evaluations in children, and consider best practices for pediatric athletes with several key cardiac conditions are detailed. The purpose of this document is to represent the first primary reference available to providers who care for pediatric athletes with cardiovascular concerns.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175017/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40175017</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.010>10.1016/j.jacc.2025.02.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175017</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Peter N Dean</dc:creator>
<dc:creator>Julie A Brothers</dc:creator>
<dc:creator>Kristin Burns</dc:creator>
<dc:creator>Jonathan B Edelson</dc:creator>
<dc:creator>Susan Etheridge</dc:creator>
<dc:creator>Dermot M Phelan</dc:creator>
<dc:creator>Keri Shafer</dc:creator>
<dc:creator>Chris Snyder</dc:creator>
<dc:creator>Silvana Molossi</dc:creator>
<dc:creator>Alfred Danielian</dc:creator>
<dc:creator>Eli M Friedman</dc:creator>
<dc:creator>Jeff Hsu</dc:creator>
<dc:creator>Mustafa Husaini</dc:creator>
<dc:creator>Eugene H Chung</dc:creator>
<dc:creator>Matthew W Martinez</dc:creator>
<dc:creator>Aaron L Baggish</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:creator>Jonathan H Kim</dc:creator>
<dc:creator>American College of Cardiology Sports &amp; Exercise Cardiology Council</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Cardiovascular Care of the Pediatric Athlete</dc:title>
<dc:identifier>pmid:40175017</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.010</dc:identifier>
</item>
<item>
<title>Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175015/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Five-year valve performance was significantly better after CoreValve/Evolut TAVR compared with surgery. Development of BVD in TAVR and surgery patients was associated with worsened 5-year clinical outcomes. (Safety and Efficacy Study of the Medtronic CoreValve System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement, NCT01240902; Safety and Efficacy Study of the Medtronic CoreValve System in the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1419-1430. doi: 10.1016/j.jacc.2025.02.009. Epub 2025 Mar 9.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The incidence and clinical importance of bioprosthetic valve dysfunction (BVD) in patients undergoing supra-annular, self-expanding transcatheter aortic valve replacement (TAVR) or surgery is not well understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to evaluate the 5-year incidence and clinical outcomes of BVD in patients undergoing CoreValve/Evolut TAVR or surgery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This post hoc analysis pooled data from the U.S. High Risk Pivotal (n = 726) and SURTAVI (n = 1,618) randomized controlled trials (RCTs), the Extreme Risk Pivotal trial (n = 608), and CoreValve Continued Access Study (n = 2,654). The primary endpoint was the incidence of BVD through 5 years from the RCTs. The association of BVD with 5-year clinical outcomes was evaluated in the pooled RCT and non-RCT populations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 5,606 patients evaluated, 3,070 (54.8%) were men, and the mean age was 82.2 ± 7.4 years. A total of 2,344 RCT patients, including 1,227 who received TAVR and 1,117 who received surgery, and 3,262 non-RCT TAVR patients were included. The rate of BVD was lower in RCT patients undergoing CoreValve/Evolut TAVR compared with surgery (9.7% vs 15.3%; subdistribution HR: 0.57; 95% CI: 0.45-0.73; P &lt; 0.001). In the pooled RCT and non-RCT cohort, BVD was associated with increased 5-year all-cause mortality (HR: 1.49; 95% CI: 1.32-1.68; P &lt; 0.001), cardiovascular mortality (HR: 1.76; 95% CI: 1.52-2.03; P &lt; 0.001), and hospitalization for valve disease or worsening heart failure (HR: 1.48; 95% CI: 1.23-1.78; P &lt; 0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Five-year valve performance was significantly better after CoreValve/Evolut TAVR compared with surgery. Development of BVD in TAVR and surgery patients was associated with worsened 5-year clinical outcomes. (Safety and Efficacy Study of the Medtronic CoreValve System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement, NCT01240902; Safety and Efficacy Study of the Medtronic CoreValve System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement [SURTAVI], NCT01586910; Safety and Efficacy Continued Access Study of the Medtronic CoreValve System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement, NCT01531374).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175015/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40175015</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.009>10.1016/j.jacc.2025.02.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175015</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Steven J Yakubov</dc:creator>
<dc:creator>Nicolas M Van Mieghem</dc:creator>
<dc:creator>Jae K Oh</dc:creator>
<dc:creator>Saki Ito</dc:creator>
<dc:creator>Kendra J Grubb</dc:creator>
<dc:creator>Daniel O'Hair</dc:creator>
<dc:creator>John K Forrest</dc:creator>
<dc:creator>Hemal Gada</dc:creator>
<dc:creator>Mubashir Mumtaz</dc:creator>
<dc:creator>G Michael Deeb</dc:creator>
<dc:creator>Gilbert H L Tang</dc:creator>
<dc:creator>Joshua D Rovin</dc:creator>
<dc:creator>Renuka Jain</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Kimberly A Skelding</dc:creator>
<dc:creator>Neal S Kleiman</dc:creator>
<dc:creator>Stanley J Chetcuti</dc:creator>
<dc:creator>Alexandra Dedrick</dc:creator>
<dc:creator>Sarah Verdoliva Boatman</dc:creator>
<dc:creator>Jeffrey J Popma</dc:creator>
<dc:creator>Michael J Reardon</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk</dc:title>
<dc:identifier>pmid:40175015</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.009</dc:identifier>
</item>
<item>
<title>Machine Learning Uncovers a New Diagnostic Threshold for Mild Aortic Stenosis in Large Observational Data Sets</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175014/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1400-1402. doi: 10.1016/j.jacc.2025.02.030.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175014/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40175014</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.030>10.1016/j.jacc.2025.02.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175014</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Bobak J Mortazavi</dc:creator>
<dc:creator>Xiaoxi Yao</dc:creator>
<dc:creator>Chenxi Huang</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Machine Learning Uncovers a New Diagnostic Threshold for Mild Aortic Stenosis in Large Observational Data Sets</dc:title>
<dc:identifier>pmid:40175014</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.030</dc:identifier>
</item>
<item>
<title>New Threshold for Defining Mild Aortic Stenosis Derived From Velocity-Encoded MRI in 60,000 Individuals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175013/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: We report a large-scale study of AV hemodynamics and identify a population threshold between normal and abnormal AV function. Mild AS, as defined by the proposed criteria, was linked to adverse outcomes in the UK Biobank and in NEDA.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1387-1399. doi: 10.1016/j.jacc.2025.01.035.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Mild aortic stenosis (AS) is associated with adverse outcomes but is incompletely defined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to examine the epidemiology of AV function measured without clinical indications.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We developed a deep learning model to measure aortic valve (AV) area, peak velocity, and mean gradient in velocity-encoded cardiac magnetic resonance imaging in 62,902 UK Biobank participants. Study findings were externally validated in NEDA (National Echo Database Australia), a clinical cohort of 365,870 people.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From measuring reference ranges of AV function in a healthy subcohort (n = 41,859), we observed a natural boundary between normal and abnormal AV hemodynamics (>;95th percentile) that we refer to as "mild AS<sub>proposed</sub>": peak velocity >;1.65 m/s, mean gradient >;4.9 mm Hg, or aortic valve area &lt;2.1 cm<sup>2</sup> (men) or &lt;1.7 cm<sup>2</sup> (women). In the full cohort, 3,676 (5.8%) participants met these novel criteria; the HR for a subsequent AV replacement for each severity category was 31.7 (mild AS<sub>proposed</sub>), 522.4 (moderate AS), and 3,057.4 (severe AS), all P &lt; 0.001. Over a mean 3.9 years of follow-up, those with mild AS<sub>proposed</sub> also had a higher risk of atrial fibrillation (110 events; HR: 1.86; P = 1.4 × 10<sup>-9</sup>) and heart failure (70 events; HR: 2.37; P = 5.9 × 10<sup>-11</sup>) compared with those without AS. In NEDA, the 101,335 participants with mild AS<sub>proposed</sub> identified with echocardiography using the same cardiac magnetic resonance imaging-defined criteria had increased all-cause mortality (HR: 1.25; 95% CI: 1.24-1.27).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We report a large-scale study of AV hemodynamics and identify a population threshold between normal and abnormal AV function. Mild AS, as defined by the proposed criteria, was linked to adverse outcomes in the UK Biobank and in NEDA.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175013/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40175013</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.035>10.1016/j.jacc.2025.01.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175013</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Shinwan Kany</dc:creator>
<dc:creator>Joel T Rämö</dc:creator>
<dc:creator>David Playford</dc:creator>
<dc:creator>Geoff Strange</dc:creator>
<dc:creator>Cody Hou</dc:creator>
<dc:creator>Sean J Jurgens</dc:creator>
<dc:creator>Victor Nauffal</dc:creator>
<dc:creator>Jonathan W Cunningham</dc:creator>
<dc:creator>Emily S Lau</dc:creator>
<dc:creator>Atul J Butte</dc:creator>
<dc:creator>Jennifer E Ho</dc:creator>
<dc:creator>Jeffrey E Olgin</dc:creator>
<dc:creator>Sammy Elmariah</dc:creator>
<dc:creator>Mark E Lindsay</dc:creator>
<dc:creator>Yih-Kai Chan</dc:creator>
<dc:creator>Simon Stewart</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:creator>James P Pirruccello</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>New Threshold for Defining Mild Aortic Stenosis Derived From Velocity-Encoded MRI in 60,000 Individuals</dc:title>
<dc:identifier>pmid:40175013</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.035</dc:identifier>
</item>
<item>
<title>Tunnelling nanotube-like structures facilitate cell-cell communication during heart development</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175708/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Apr 2. doi: 10.1038/s41569-025-01151-0. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175708/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40175708</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01151-0>10.1038/s41569-025-01151-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175708</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Tunnelling nanotube-like structures facilitate cell-cell communication during heart development</dc:title>
<dc:identifier>pmid:40175708</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01151-0</dc:identifier>
</item>
<item>
<title>Reply: Optimizing Care During the "Golden Day of Shock"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175023/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1469. doi: 10.1016/j.jacc.2025.01.031.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175023/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40175023</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.031>10.1016/j.jacc.2025.01.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175023</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Van-Khue Ton</dc:creator>
<dc:creator>Song Li</dc:creator>
<dc:creator>Navin K Kapur</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Optimizing Care During the "Golden Day of Shock"</dc:title>
<dc:identifier>pmid:40175023</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.031</dc:identifier>
</item>
<item>
<title>Challenges in Applying the CSWG-SCAI Shock Classification: Insights and Considerations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175022/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1467-1468. doi: 10.1016/j.jacc.2024.09.1250.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175022/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40175022</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1250>10.1016/j.jacc.2024.09.1250</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175022</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Guglielmo Gallone</dc:creator>
<dc:creator>Jorge A Ortega-Hernandez</dc:creator>
<dc:creator>Pier Paolo Bocchino</dc:creator>
<dc:creator>Luca Baldetti</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Challenges in Applying the CSWG-SCAI Shock Classification: Insights and Considerations</dc:title>
<dc:identifier>pmid:40175022</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1250</dc:identifier>
</item>
<item>
<title>Serial Shock Severity Assessment Investigation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175021/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1466. doi: 10.1016/j.jacc.2024.09.1249.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175021/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40175021</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1249>10.1016/j.jacc.2024.09.1249</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175021</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Harry B Peled</dc:creator>
<dc:creator>Nhu Quyen Dau</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Serial Shock Severity Assessment Investigation</dc:title>
<dc:identifier>pmid:40175021</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1249</dc:identifier>
</item>
<item>
<title>Reply: The Drug-Coated Balloon-Bifurcation Trial (DCB-BIF): A Flash in the Pan?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175020/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1465. doi: 10.1016/j.jacc.2025.01.032.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175020/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40175020</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.032>10.1016/j.jacc.2025.01.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175020</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Xiaofei Gao</dc:creator>
<dc:creator>Shao-Liang Chen</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: The Drug-Coated Balloon-Bifurcation Trial (DCB-BIF): A Flash in the Pan?</dc:title>
<dc:identifier>pmid:40175020</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.032</dc:identifier>
</item>
<item>
<title>The Drug-Coated Balloon-Bifurcation Trial (DCB-BIF): A Flash in the Pan?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175019/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1464. doi: 10.1016/j.jacc.2024.12.034.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175019/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40175019</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.034>10.1016/j.jacc.2024.12.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175019</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Leontin Lazar</dc:creator>
<dc:creator>Bharat Khialani</dc:creator>
<dc:creator>Bernardo Cortese</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Drug-Coated Balloon-Bifurcation Trial (DCB-BIF): A Flash in the Pan?</dc:title>
<dc:identifier>pmid:40175019</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.034</dc:identifier>
</item>
<item>
<title>FDA's Proposed Nicotine Regulations: A New Frontier for Cardiovascular Health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175018/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1459-1461. doi: 10.1016/j.jacc.2025.02.022.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175018/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40175018</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.022>10.1016/j.jacc.2025.02.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175018</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Kushal T Kadakia</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>FDA's Proposed Nicotine Regulations: A New Frontier for Cardiovascular Health</dc:title>
<dc:identifier>pmid:40175018</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.022</dc:identifier>
</item>
<item>
<title>Bioprosthetic Aortic Valve Durability and Performance: Implications for Lifetime Management of Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1431-1433. doi: 10.1016/j.jacc.2025.02.029. Epub 2025 Mar 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40175016</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.029>10.1016/j.jacc.2025.02.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175016</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Samir R Kapadia</dc:creator>
<dc:creator>Grant W Reed</dc:creator>
<dc:creator>Rishi Puri</dc:creator>
<dc:creator>James Yun</dc:creator>
<dc:creator>Amar Krishnaswamy</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Bioprosthetic Aortic Valve Durability and Performance: Implications for Lifetime Management of Aortic Stenosis</dc:title>
<dc:identifier>pmid:40175016</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.029</dc:identifier>
</item>
<item>
<title>Incidence, risk factors, and mortality of pulmonary embolism in the Netherlands (2015-22): sex differences and shifts during the coronavirus disease 2019 pandemic</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40172984/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The seemingly favourable pre-pandemic temporal trends in PE epidemiology in the Netherlands reversed during the COVID-19 pandemic but appear to revert to pre-pandemic levels after 2022.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf211. doi: 10.1093/eurheartj/ehaf211. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Epidemiology of pulmonary embolism (PE) may have shifted since the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to describe temporal trends in PE epidemiology in the Netherlands since 2015.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using nationwide data from Statistics Netherlands, all Dutch inhabitants (>;16 million) without a history of PE were dynamically identified on 1 January of each year to assemble eight cohorts of PE-free Dutch inhabitants in 2015-22. They were individually followed until the end of that respective year to determine 1-year risk of PE (identified by hospital diagnoses/primary cause of death) and establish relevant risk factors. The PE cases were subsequently studied to determine 1-year all-cause mortality following PE. Multivariable logistic regression with cluster-robust standard errors and robust Poisson regression were respectively employed to evaluate relative differences in PE incidence and mortality between years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Pulmonary embolism incidence in the Dutch population decreased from 2015 to 2019 but markedly increased by 23% (95% confidence interval 20%-26%), 52% (48%-56%), and 7% (4%-9%) in 2020-22 (vs. 2019), respectively. Most traditional PE risk factors remained associated with PE in 2020-22 but generally with a weaker association. Pulmonary embolism mortality was stable until 2019 but then increased by 10% (6%-14%) in 2020 and 9% (6%-13%) in 2021, while the increase [2% (-1% to 6%)] was insignificant in 2022. The above-mentioned changes since 2020 were generally greater in males than females.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The seemingly favourable pre-pandemic temporal trends in PE epidemiology in the Netherlands reversed during the COVID-19 pandemic but appear to revert to pre-pandemic levels after 2022.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40172984/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40172984</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf211>10.1093/eurheartj/ehaf211</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40172984</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Qingui Chen</dc:creator>
<dc:creator>Nienke van Rein</dc:creator>
<dc:creator>Luuk J J Scheres</dc:creator>
<dc:creator>Eva K Kempers</dc:creator>
<dc:creator>Chantal Visser</dc:creator>
<dc:creator>Marieke J H A Kruip</dc:creator>
<dc:creator>Suzanne C Cannegieter</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Incidence, risk factors, and mortality of pulmonary embolism in the Netherlands (2015-22): sex differences and shifts during the coronavirus disease 2019 pandemic</dc:title>
<dc:identifier>pmid:40172984</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf211</dc:identifier>
</item>
<item>
<title>Comparing cardiology curricula: Europe vs. USA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40172953/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf105. doi: 10.1093/eurheartj/ehaf105. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40172953/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40172953</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf105>10.1093/eurheartj/ehaf105</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40172953</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Justin Brilliant</dc:creator>
<dc:creator>Floran Sahiti</dc:creator>
<dc:creator>Christine Mages</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Comparing cardiology curricula: Europe vs. USA</dc:title>
<dc:identifier>pmid:40172953</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf105</dc:identifier>
</item>
<item>
<title>Accountable Care Organization Participation and Cardiovascular Care Quality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40172907/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Participation in an MSSP ACO was not found to be associated with early improvement in quality measures at outpatient cardiology practices.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Apr 2. doi: 10.1001/jamacardio.2025.0381. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The Medicare Shared Savings Program (MSSP) was introduced in 2012 to improve care quality and lower costs to Medicare. Under this program, accountable care organizations (ACOs) assumed responsibility for costs and care quality for a group of Medicare beneficiaries.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To compare changes in quality measures for patients at outpatient cardiology practices before and after their participation in a Medicare Shared Savings Program ACO.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This pre-post cohort study comparing quality prior to and after ACO participation evaluated the MSSP at 83 ACO outpatient cardiology practices compared with 332 non-ACO-participating cardiology practices, adjusted for secular trends, using 15 performance measures in the National Cardiovascular Data Registry PINNACLE (Practice Innovation and Clinical Excellence) Registry from January 1, 2013, through March 31, 2019. Data analysis was performed from 2022 to 2025.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Outpatient cardiology practice participation in the MSSP, which allows ACOs to share in the savings if predetermined cost targets are met, with payments adjusted based on a quality performance score.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Primary end points included 15 quality measures for coronary artery disease, heart failure, atrial fibrillation, and hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During the study period, 2 390 244 patients (1 273 615 [53.3%] female; mean [SD] age, 58.5 [17.7] years) were cared for by 83 ACO practices, and 5 415 880 patients (2 810 204 [51.9%] female; mean [SD] age, 61.5 [16.3] years) were cared for by 332 non-ACO practices. Outpatient cardiology practice participation in an MSSP ACO was not associated with differential changes in various performance measures for coronary artery disease, heart failure, atrial fibrillation, and hypertension. There were no differential changes in the odds of β-blocker prescription, blood pressure control, antiplatelet prescription, angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) prescription, low-density lipoprotein (LDL) profiles, or smoking cessation for coronary artery disease; left ventricular assessment, β-blocker prescription, ACEI or ARB prescription, or implantable cardioverter defibrillator use for heart failure; anticoagulation for atrial fibrillation; or blood pressure control for hypertension. Exploratory analyses extending follow-up to 24 months revealed an increase in β-blocker use for heart failure (adjusted odds ratio [aOR], 1.23; 95% CI, 1.02-1.49; P = .03) and a decline in LDL profiles less than 100 mg/dL (to convert to millimoles per liter, multiply by 0.0259; aOR, 0.71; 95% CI, 0.51-0.999; P = .049). Among a subset of traditional Medicare patients, there was an increase in implantable cardioverter defibrillator use by 12 months (aOR, 1.66; 95% CI, 1.12-2.45; P = .01) following ACO participation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Participation in an MSSP ACO was not found to be associated with early improvement in quality measures at outpatient cardiology practices.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40172907/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40172907</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0381>10.1001/jamacardio.2025.0381</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40172907</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Erica S Spatz</dc:creator>
<dc:creator>D August Oddleifson</dc:creator>
<dc:creator>Jehanzeb Kayani</dc:creator>
<dc:creator>Kensey L Gosch</dc:creator>
<dc:creator>Philip G Jones</dc:creator>
<dc:creator>Rushabh H Doshi</dc:creator>
<dc:creator>Thomas M Maddox</dc:creator>
<dc:creator>Nihar R Desai</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Accountable Care Organization Participation and Cardiovascular Care Quality</dc:title>
<dc:identifier>pmid:40172907</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0381</dc:identifier>
</item>
<item>
<title>Adverse Pregnancy Outcomes and N-Terminal Pro-Brain Natriuretic Peptide Levels 2 to 7 Years After Delivery: The nuMoM2b Heart Health Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40172904/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Apr 2. doi: 10.1001/jamacardio.2025.0325. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40172904/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40172904</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0325>10.1001/jamacardio.2025.0325</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40172904</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Priya M Freaney</dc:creator>
<dc:creator>Xiaoning Huang</dc:creator>
<dc:creator>Lucia C Petito</dc:creator>
<dc:creator>William A Grobman</dc:creator>
<dc:creator>Janet Catov</dc:creator>
<dc:creator>Alisse Hauspurg</dc:creator>
<dc:creator>C Noel Bairey Merz</dc:creator>
<dc:creator>Natalie Bello</dc:creator>
<dc:creator>Jin Kyung Kim</dc:creator>
<dc:creator>Abbi Lane</dc:creator>
<dc:creator>David M Haas</dc:creator>
<dc:creator>Lisa D Levine</dc:creator>
<dc:creator>Rebecca B McNeil</dc:creator>
<dc:creator>Eliza Miller</dc:creator>
<dc:creator>George Saade</dc:creator>
<dc:creator>Lauren Theilen</dc:creator>
<dc:creator>Lynn M Yee</dc:creator>
<dc:creator>Jasmina Varagic</dc:creator>
<dc:creator>Brian Mercer</dc:creator>
<dc:creator>Uma Reddy</dc:creator>
<dc:creator>Donald M Lloyd-Jones</dc:creator>
<dc:creator>Philip Greenland</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>National Heart, Lung, and Blood Institute nuMoM2b Heart Health Study Network</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Adverse Pregnancy Outcomes and N-Terminal Pro-Brain Natriuretic Peptide Levels 2 to 7 Years After Delivery: The nuMoM2b Heart Health Study</dc:title>
<dc:identifier>pmid:40172904</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0325</dc:identifier>
</item>
<item>
<title>Hypertensive Disorders of Pregnancy and Long-Term Risk of Dilated Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40172877/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Patients with hypertensive disorders of pregnancy had a greater risk of developing dilated cardiomyopathy. Older maternal age and postpartum hypertension were associated with higher risk of dilated cardiomyopathy after a hypertensive disorder of pregnancy. These findings support long-term clinical vigilance of patients with a history of hypertensive disorders of pregnancy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Apr 2. doi: 10.1001/jamacardio.2025.0328. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The impact of hypertensive disorders of pregnancy on developing dilated cardiomyopathy is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine whether hypertensive disorders of pregnancy are associated with long-term risk of dilated cardiomyopathy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study performed in England used the following linked electronic health records databases: Clinical Practice Research Datalink (CPRD) Pregnancy Register, CPRD Aurum (primary care), Hospital Episode Statistics Admitted Patient Care, and Office for National Statistics mortality data. Participants included an exposed cohort of 14 083 patients in their first pregnancy with hypertensive disorders of pregnancy (index date observed: January 1997 to December 2018; followed up until July 2023) and unexposed cohort of 70 415 with normotensive pregnancies randomly sampled from the Pregnancy Register (5:1 ratio).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Hypertensive disorder of pregnancy (preeclampsia, gestational hypertension).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Cox proportional hazards models were fitted to estimate hazard ratios (HRs) of developing dilated cardiomyopathy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The cohort included 14 083 individuals with a hypertensive disease of pregnancy during their first pregnancy and 70 415 individuals with normotensive first pregnancies. A first-time pregnancy complicated by a hypertensive disorder of pregnancy, compared with a normotensive first-time pregnancy, was associated with a 93% higher risk of developing dilated cardiomyopathy (adjusted HR, 1.93 [95% CI, 1.33-2.81]; P = .001; adjusted for maternal age). Dilated cardiomyopathy developed a median (IQR) of 5.1 (0.7-10.6) years post partum in those with HDP and 10.6 (4.2-15.8) years post partum in those with normotensive first pregnancies. The association remained significant after adjusting for maternal age, birth year, gestational diabetes, postpregnancy diabetes, postpregnancy hypertension, total parity, ethnicity, and socioeconomic status (adjusted HR, 1.55 [95% CI, 1.04-2.31]; P = .03). There was a dose response; there was a higher risk of DCM in those with preeclampsia (adjusted HR, 1.85 [95% CI, 1.24-2.76]; P = .002) and severe preeclampsia (adjusted HR, 4.29 [95% CI, 2.32-7.96]; P &lt; .001). Maternal age (adjusted HR per year of age, 1.06 [95% CI, 1.03-1.08]; P &lt; .001) and postpartum incident hypertension (adjusted HR, 1.68 [95% CI, 1.16-2.42]; P = .006) were independently associated with the development of DCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with hypertensive disorders of pregnancy had a greater risk of developing dilated cardiomyopathy. Older maternal age and postpartum hypertension were associated with higher risk of dilated cardiomyopathy after a hypertensive disorder of pregnancy. These findings support long-term clinical vigilance of patients with a history of hypertensive disorders of pregnancy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40172877/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40172877</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0328>10.1001/jamacardio.2025.0328</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40172877</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Upasana Tayal</dc:creator>
<dc:creator>Constantinos Kallis</dc:creator>
<dc:creator>Georgie M Massen</dc:creator>
<dc:creator>Nora Rossberg</dc:creator>
<dc:creator>Emily L Graul</dc:creator>
<dc:creator>Jennifer K Quint</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Hypertensive Disorders of Pregnancy and Long-Term Risk of Dilated Cardiomyopathy</dc:title>
<dc:identifier>pmid:40172877</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0328</dc:identifier>
</item>
<item>
<title>Grading valve regurgitation by AI is solved: What's next?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40172299/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf257. doi: 10.1093/eurheartj/ehaf257. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40172299/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40172299</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf257>10.1093/eurheartj/ehaf257</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40172299</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Neal Yuan</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Grading valve regurgitation by AI is solved: What's next?</dc:title>
<dc:identifier>pmid:40172299</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf257</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40172094/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Feb 28;136(5):453-454. doi: 10.1161/RES.0000000000000710. Epub 2025 Feb 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40172094/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40172094</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000710>10.1161/RES.0000000000000710</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40172094</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:date>2025-04-02</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:40172094</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000710</dc:identifier>
</item>
<item>
<title>Transcatheter vs. surgical aortic valve replacement in women: the RHEIA trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40171878/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250403061228&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among women with severe aortic stenosis, the incidence of the composite of death, stroke, or rehospitalization at 1 year was lower with TAVI than with surgery.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 2:ehaf133. doi: 10.1093/eurheartj/ehaf133. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Although women with severe symptomatic aortic stenosis have more complications than men when undergoing surgical valve replacement, they are under-represented in clinical trials. The Randomized researcH in womEn all comers wIth Aortic stenosis (RHEIA) trial investigates the balance of benefits and risks of transcatheter aortic valve implantation (TAVI) vs. surgery in women.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Women were randomized 1:1 to transfemoral TAVI with a balloon-expandable valve or surgery. The primary composite endpoint was death, stroke, or (valve, procedure or heart failure related) rehospitalization at 1 year. Non-inferiority testing with a pre-specified 6% margin and superiority testing were performed in the as-treated population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At 48 European centres, 443 women underwent randomization, and 420 were treated as randomized. Mean age was 73 years, and the mean estimated surgical risk of death was 2.1% (Society of Thoracic Surgeons risk score). Kaplan-Meier estimates of the primary endpoint event rates at 1 year were 8.9% in the TAVI and 15.6% in the surgery group. This difference of -6.8% with an upper 95% confidence limit of -1.5% demonstrated the non-inferiority of TAVI (P &lt; .001). The two-sided 95% confidence interval of -13.0% to -.5% further resulted in superiority (P = .034). The 1-year incidence of the primary endpoint components was: .9% with TAVI vs. 2.0% with surgery for death from any cause, 3.3% vs. 3.0% for stroke, and 5.8% vs. 11.4% for rehospitalization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among women with severe aortic stenosis, the incidence of the composite of death, stroke, or rehospitalization at 1 year was lower with TAVI than with surgery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS.GOV NUMBER: NCT04160130.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40171878/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250403061228&v=2.18.0.post9+e462414">40171878</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf133>10.1093/eurheartj/ehaf133</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40171878</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Didier Tchetche</dc:creator>
<dc:creator>Philippe Pibarot</dc:creator>
<dc:creator>Jeroen J Bax</dc:creator>
<dc:creator>Nikolaos Bonaros</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Nicolas Dumonteil</dc:creator>
<dc:creator>Fabian Nietlispach</dc:creator>
<dc:creator>David Messika-Zeitoun</dc:creator>
<dc:creator>Stuart J Pocock</dc:creator>
<dc:creator>Pierre Berthoumieu</dc:creator>
<dc:creator>Martin J Swaans</dc:creator>
<dc:creator>Leo Timmers</dc:creator>
<dc:creator>Tanja Katharina Rudolph</dc:creator>
<dc:creator>Sabine Bleiziffer</dc:creator>
<dc:creator>Lionel Leroux</dc:creator>
<dc:creator>Thomas Modine</dc:creator>
<dc:creator>Frank van der Kley</dc:creator>
<dc:creator>Vincent Auffret</dc:creator>
<dc:creator>Jacques Tomasi</dc:creator>
<dc:creator>Lukas Stastny</dc:creator>
<dc:creator>Christian Hengstenberg</dc:creator>
<dc:creator>Martin Andreas</dc:creator>
<dc:creator>Florence Leclercq</dc:creator>
<dc:creator>Thomas Gandet</dc:creator>
<dc:creator>Julia Mascherbauer</dc:creator>
<dc:creator>Karola Trescher</dc:creator>
<dc:creator>Bernard Prendergast</dc:creator>
<dc:creator>Mariuca Vasa-Nicotera</dc:creator>
<dc:creator>Alaide Chieffo</dc:creator>
<dc:creator>Jan Mares</dc:creator>
<dc:creator>Wilbert Wesselink</dc:creator>
<dc:creator>Radka Rakova</dc:creator>
<dc:creator>Jana Kurucova</dc:creator>
<dc:creator>Peter Bramlage</dc:creator>
<dc:creator>Helene Eltchaninoff</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transcatheter vs. surgical aortic valve replacement in women: the RHEIA trial</dc:title>
<dc:identifier>pmid:40171878</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf133</dc:identifier>
</item>





























</channel>
</rss>